The ATF6 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell pool derived from the human lung adenocarcinoma A-549 line. This population harbors diverse gene-disrupting mutations at the ATF6 locus, establishing a loss-of-function model devoid of full-length ATF6 expression. The polyclonal format reduces clonal artifacts and enables robust population-based analyses of endoplasmic reticulum (ER) stress and unfolded protein response (UPR) signaling in an epithelial cancer context.
The A-549 parental cells originate from a 58-year-old Caucasian male with lung carcinoma and serve as a widely used model of alveolar type II epithelial cells. They retain key adenocarcinoma features, including KRAS mutation, and are a cornerstone of respiratory disease and oncology research. The ATF6 knockout in this background allows investigation of how ER stress pathways influence tumor biology, drug sensitivity, and metabolic adaptation intrinsic to non-small cell lung cancer.
ATF6 is an ER-resident transcription factor activated by proteolytic cleavage upon ER stress. Under stress, ATF6 dissociates from the chaperone HSPA5 (BiP) and traffics to the Golgi, where sequential processing by MBTPS1 (S1P) and MBTPS2 (S2P) releases the N-terminal fragment. This fragment translocates to the nucleus, partners with NF-Y transcription factors, and binds ERSE/CRE elements to upregulate target genes. Downstream effectors include the chaperones HSPA5 and HSP90B1, the oxidoreductase PDIA4, the ERAD component EDEM1, and the transcription factor XBP1, collectively restoring ER homeostasis.
In A-549 lung adenocarcinoma cells, ATF6 knockout provides a clinically relevant platform to dissect the UPR??s role in cancer cell survival under microenvironmental stresses such as hypoxia and nutrient deprivation. This model is also relevant to ER stress-related pathologies including neurodegenerative disorders and metabolic syndrome. By eliminating ATF6-dependent signaling, researchers can delineate the contributions of this branch to tumor progression, apoptosis resistance, and adaptation, potentially identifying therapeutic vulnerabilities.
These cells are suitable for a range of assays including western blotting for ATF6 cleavage, RT-qPCR quantification of HSPA5 and EDEM1 transcripts, and immunofluorescence tracking of ATF6 localization. ERSE-luciferase reporter assays measure UPR transcriptional activity, while viability assays under tunicamycin or thapsigargin assess stress resilience. The polyclonal pool facilitates high-throughput screening of UPR modulators and drug target validation. For further technical support or to inquire about custom engineering services, please contact Ascent Research.
